Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection.
BACKGROUND
Posttransplantation measurement of soluble CD30 (sCD30) may be useful for identifying kidney graft recipients at risk of impending graft rejection in the early posttransplantation period.


METHODS
We measured plasma sCD30 levels and evaluated the levels in relation to the diagnosis of rejection.


RESULTS
Receiver operating characteristic curves demonstrated that on posttransplantation days 3 to 5, sCD30 allowed a differentiation of recipients who subsequently developed acute allograft rejection (n=25) from recipients with an uncomplicated course (n=20, P<0.0001) (area under the receiver operating characteristic curve 0.96, specificity 100%, sensitivity 88%) and recipients with acute tubular necrosis in the absence of rejection (n=11, P=0.001) (area under the receiver operating characteristic curve 0.85, specificity 91%, sensitivity 72%).


CONCLUSIONS
sCD30 measured on posttransplantation days 3 to 5 offers a noninvasive means for differentiating patients with impending acute allograft rejection from patients with an uncomplicated course or with acute tubular necrosis.
Pelzl
Steffen
S
Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany.
Opelz
Gerhard
G
Daniel
Volker
V
Wiesel
Manfred
M
Süsal
Caner
C
D000208:Acute Disease; D000328:Adult; D015415:Biomarkers; D005069:Evaluation Studies as Topic; D005260:Female; D006084:Graft Rejection / Q000097:blood* / Q000175:diagnosis*; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012995:Solubility; D014184:Transplantation, Homologous
D015415:Biomarkers; D017730:Ki-1 Antigen